EUVIMED · CrossrefZeitschrift
Clinical Lung Cancer
ISSN 1525-7304 · Elsevier BV
Neueste Artikel
Pretreatment FDG-PET Biomarkers Predict Regional and Distant Failure but Not Local Recurrence Following Modern Use of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Real-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-Year Update
Stage I Lung Adenocarcinoma in Young Patients (Aged ≤ 50 Years): Beyond Female Nonsmokers
Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416)
Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting
Comparative Effectiveness of First-Line Tyrosine Kinase Inhibitors in ALK-Positive Metastatic Non–Small Cell Lung Cancer by Presence of Brain Metastases
Low Baseline Absolute Neutrophil Count and Chemotherapy Safety in African American Patients with Advanced Lung Cancer: A Retrospective Cohort Study
Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD
The Impact of Tumor Immune Microenvironment in EGFR-Mutant Non-Small Cell Lung Cancer on the Efficacy of Osimertinib
Assessment of Prognostic Value of CEACAM5 Expression Using Archival Tissue and Real-World Evidence of Metastatic Patients with NSCLC in United States
Durable Response After Pembrolizumab for Recurrent Tracheal Squamous Cell Carcinoma: A Case Report and Focused Literature Review
Racial Disparities in Thymic Epithelial Tumors: Insights From a Multiracial Urban Cohort
A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non–Small Cell Lung Cancer: JCOG2510 (PRIME-CRT)
Corrigendum to “Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer” [Clinical Lung Cancer 26 (2025) 573-582]
Utility of longitudinal serum tumor markers for disease monitoring in advanced NSCLC with actionable genomic alterations
Safety and Efficacy of Stereotactic body radiotherapy for central and ultracentral Early-Stage Lung Tumors: A Canadian Provincial Cancer Center Experience.
Transforming the Therapeutic Landscape of HER2-Mutant NSCLC: Emerging First-Line Treatment Strategies
SAARC Consensus Recommendations for the diagnosis and treatment of non-small-cell lung cancer (NSCLC)
Etiologies and Outcomes of Respiratory Failure After Immune Checkpoint Inhibitor Therapy
Conversion Surgery After EGFR-TKI Induction for Initially Unresectable EGFR-Mutant Stage III NSCLC
Exploring Thoracic Radiotherapy in Metastatic NSCLC: A Retrospective Review in the Era of Immunotherapy and Targeted Therapies
Lost to Follow-up: Social Determinants and Patient Perceptions in Lung Cancer Screening Adherence
Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer in Patients Aged 80 Years and Older: A Single-Center Retrospective Cohort Study of Octogenarians and Nonagenarians
Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy
Effects of Sex on Mortality in Patients With Lung Cancer: A Multiple Mediation Analysis of The Boston Lung Cancer Study
Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use
A United States-Based Real-World Study on Biomarker Testing and Rebiopsy Rates Among Patients With Non-Small Cell Lung Cancer Across Lines of Therapy
A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2)
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung
EUVIMED